Drugs / NTX-1088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05378425 | Sep 2022 → Dec 2026 expected | metastatic malignant neoplasm | Nectin Therapeutics Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-1088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05378425 ↗ |
| Modality | Monoclonal antibody | “IgG4 mAb targeting the poliovirus receptor (PVR, CD155).” NCT05378425 ↗ |
| Route | Intravenous | “intravenously (IV) administered NTX-1088” NCT05378425 ↗ |
| Target | PVR | “IgG4 mAb targeting the poliovirus receptor (PVR, CD155).” NCT05378425 ↗ |